A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis
← catalyst calendarSponsored by Celltrion (industry) · 068270.KS — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
153actual
Sites
1
Country
Poland
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-26 | actual | When the study began enrolling |
| Primary completion | 2026-02-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Plaque Psoriasis
Interventions
- Biological: CT-P55
- Biological: EU-approved Cosentyx
Primary outcome
what the primary-completion date above is the date OFPercent change from baseline in Psoriasis Area and Severity Index (PASI) score
measured Week8
Permalink · 068270.KS's whole pipeline · Catalyst calendar · Every registered study · What changed